Email this article Efficacy of dupilumab in real practice in the treatment of severe forms of asthma and atopic dermatitis (comparative retrospective study)
- Authors: Fomina D.S.1,2, Fedosenko S.V.3, Bobrikova E.N.1, Chernov A.A.1,4, Mukhina O.A.1, Lebedkina M.S.1, Karaulov A.V.2, Nurtazina A.Y.1,2, Lysenko M.A.1,5
-
Affiliations:
- City Clinical Hospital №52
- Sechenov First Moscow State Medical University (Sechenov University)
- Siberian State Medical University
- Russian Medical Academy of Continuous Professional Education
- Pirogov Russian National Research Medical University
- Issue: Vol 95, No 7 (2023)
- Pages: 568-573
- Section: Original articles
- URL: https://journals.rcsi.science/0040-3660/article/view/148298
- DOI: https://doi.org/10.26442/00403660.2023.07.202309
- ID: 148298
Cite item
Full Text
Abstract
Background. Dupilumab, a fully human monoclonal antibody directed against the common α-subunit of interleukin (IL)-4 receptors and blocking signaling from both IL-4 and IL-13, may be recommended for the treatment of moderate to severe atopic dermatitis (AD) and bronchial asthma (BA).
Aim. To perform a comparative assessment of the effectiveness of maintenance therapy with dupilumab in patients with severe BA as the main indication for genetically engineered biological drugs and in patients with severe asthma with concomitant severe AD as the indication for targeted therapy.
Materials and methods. A 6-month retrospective comparative study was performed at the specialized reference center for allergology and immunology. The study included 115 adult patients of both sexes treated with dupilumab for uncontrolled severe asthma as the main indication for targeted therapy (BA group; n=65) or for a combination of severe uncontrolled asthma and severe AD (BAAD; n=50). Dupilumab was administered subcutaneously for 6 months. The first dose was 600 mg once and then 300 mg Q2W. Evaluation of the effectiveness of dupilumab therapy at 6 months of treatment in both groups included achieving asthma control (ACT, ACQ5), improving pulmonary function test, reducing the risk of exacerbations and the need for systemic glucocorticosteroids (SGCS), improving quality of life (AQLQ), change of biomarkers (FeNO, eosinophil count) and the course of comorbid diseases, including improvement in the AD (SCORAD, EASI) and rhinosinusitis polyposa (SNOT-22).
Results and conclusion. During dupilumab therapy, in a significant proportion of patients, regardless of the presence or absence of other T2-associated diseases (e.g., AD or rhinosinusitis polyposa), an improvement in asthma was demonstrated as early as in the first 6 months of treatment with dupilumab in all recommended domains for assessing the response to targeted therapy: improving asthma control and respiratory function, reducing the frequency of moderate and severe exacerbations associated with the use of SGCS and/or hospitalization, a positive effect on the quality of life and the comorbid diseases, as well as a cumulative reduction in the need for SGCS.
Full Text
##article.viewOnOriginalSite##About the authors
Daria S. Fomina
City Clinical Hospital №52; Sechenov First Moscow State Medical University (Sechenov University)
Email: sbornaya1med@yandex.ru
ORCID iD: 0000-0002-5083-6637
канд. мед. наук, доц., рук. Московского городского научно-практического центра аллергологии и иммунологии, доц. каф. клинической иммунологии и аллергологии
Russian Federation, Moscow; MoscowSergey V. Fedosenko
Siberian State Medical University
Email: sbornaya1med@yandex.ru
ORCID iD: 0000-0001-6655-3300
д-р мед. наук, проф. каф. общей врачебной практики и поликлинической терапии
Russian Federation, TomskElena N. Bobrikova
City Clinical Hospital №52
Email: sbornaya1med@yandex.ru
ORCID iD: 0000-0002-6534-5902
зав. консультативно-диагностическим отд-нием Московского городского научно-практического центра аллергологии и иммунологии
Russian Federation, MoscowAnton A. Chernov
City Clinical Hospital №52; Russian Medical Academy of Continuous Professional Education
Author for correspondence.
Email: sbornaya1med@yandex.ru
ORCID iD: 0000-0001-6209-387X
врач-терапевт отд. клинической фармакологии, мл. науч. сотр. НИИ молекулярной и персонализированной медицины
Russian Federation, Moscow; MoscowOlga A. Mukhina
City Clinical Hospital №52
Email: sbornaya1med@yandex.ru
ORCID iD: 0000-0002-3794-4991
врач – аллерголог-иммунолог консультативно-диагностического отд-ния Московского городского научно-практического центра аллергологии и иммунологии
Russian Federation, MoscowMarina S. Lebedkina
City Clinical Hospital №52
Email: sbornaya1med@yandex.ru
ORCID iD: 0000-0002-9545-4720
врач – аллерголог-иммунолог консультативно-диагностического отд-ния Московского городского научно-практического центра аллергологии и иммунологии
Russian Federation, MoscowAlexander V. Karaulov
Sechenov First Moscow State Medical University (Sechenov University)
Email: sbornaya1med@yandex.ru
ORCID iD: 0000-0002-1930-5424
акад. РАН, д-р мед. наук, проф., зав. лаб. иммунопатологии Института молекулярной медицины, зав. каф. клинической иммунологии и аллергологии Института клинической медицины им. Н.В. Склифосовского
Russian Federation, MoscowAsel Yu. Nurtazina
City Clinical Hospital №52; Sechenov First Moscow State Medical University (Sechenov University)
Email: sbornaya1med@yandex.ru
ORCID iD: 0000-0002-2337-3307
врач – аллерголог-иммунолог ГБУЗ «ГКБ №52», ассистент каф. клинической иммунологии и аллергологии
Russian Federation, Moscow; MoscowMariana A. Lysenko
City Clinical Hospital №52; Pirogov Russian National Research Medical University
Email: sbornaya1med@yandex.ru
ORCID iD: 0000-0001-6010-7975
д-р мед. наук, глав. врач, проф. каф. общей терапии фак-та дополнительного профессионального образования
Russian Federation, Moscow; MoscowReferences
- Castro M, Corren J, Pavord ID, et al. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. N Engl J Med. 2018;378(26):2486-96. doi: 10.1056/NEJMoa1804092
- Harvey ES, Langton D, Katelaris C, et al. Mepolizumab effectiveness and identification of super-responders in severe asthma. Eur Respir J. 2020;55(5):1902420. doi: 10.1183/13993003.02420-2019
- Eger K, Kroes JA, Ten Brinke A, Bel EH. Long-Term Therapy Response to Anti-IL-5 Biologics in Severe Asthma-A Real-Life Evaluation. J Allergy Clin Immunol Pract. 2021;9(3):1194-200. doi: 10.1016/j.jaip.2020.10.010
- Menzies-Gow A, Hoyte FL, Price DB, et al. Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab. Adv Ther. 2022;39(5):2065-84. doi: 10.1007/s12325-022-02098-1
- Atayık E, Aytekin G. A Single Center Experience of Super-Responders Among Severe Asthma Patients Receiving Treatment with Mepolizumab. Turk Thorac J. 2022;23(5):348-54. doi: 10.5152/TurkThoracJ.2022.22023
- Calzetta L, Rogliani P. Letter to the Editor Regarding "Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab". Adv Ther. 2022;39(8):3857-61. doi: 10.1007/s12325-022-02213-2
- Marks GB, Dunn SM, Woolcock AJ. An evaluation of an asthma quality of life questionnaire as a measure of change in adults with asthma. J Clin Epidemiol. 1993;46(10):1103-11. doi: 10.1016/0895-4356(93)90109-e
- Agache I, Akdis CA, Akdis M, et al. Biologicals Guidelines-Recommendations for severe asthma. Allergy. 2021;76(1):14-44. doi: 10.1111/all.14425
- Rabe KF, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378:2475-85. doi: 10.1056/NEJMoa1804093
- de Bruin-Weller M, Thaçi D, Smith CH, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ). Br J Dermatol. 2018;178(5):1083-101. doi: 10.1111/bjd.16156
Supplementary files
